<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264639</url>
  </required_header>
  <id_info>
    <org_study_id>APL-CP0514</org_study_id>
    <nct_id>NCT02264639</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH</brief_title>
  <official_title>An Open Label, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL-2 as an Add-On to Standard of Care in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apellis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apellis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be the initial exploration of APL-2 in patients with PNH. The assessments of
      the safety, tolerability, PK, and PD following administration of single and multiples doses
      of APL-2 will guide decisions to further develop the drug.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability.</measure>
    <time_frame>Five months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Parameters</measure>
    <time_frame>Five months</time_frame>
    <description>Cmax
Maximum Concentration (Cmax)
Time to Cmax (Tmax)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First Dose 25mg, Repeated Dose 5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First Dose 50 mg, Repeated Dose 30 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated Dose 180 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated Dose 270 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (Intra-subject)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>optional intra-subject repeated dose 360mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL-2</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 4 (Intra-subject)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female

          2. At least 18 years of age

          3. Weigh &gt;55 kg

          4. Diagnosed with PNH

          5. On treatment with eculizumab (SolirisÂ®) for at least 3 months

          6. Hb &lt; 10 g/dL at screening OR have received at least one transfusion within 12 months
             prior to screening

          7. Platelet count of &gt;30,000/mm3

          8. Absolute neutrophil count &gt; 500/mm3

          9. Women of child-bearing potential (WOCBP) must have a negative pregnancy test at
             screening and must agree to use protocol defined methods of contraception for the
             duration of the study (see below)

         10. Males with female partners of child bearing potential must agree to use protocol
             defined methods of contraception (see below) and agree to refrain from donating sperm
             for the duration of the study

         11. Willing and able to give informed consent

        Exclusion Criteria:

          1. Active bacterial infection

          2. Known infection with hepatitis B, C or HIV

          3. Hereditary complement deficiency

          4. History of bone marrow transplantation

          5. Participation in any other investigational drug trial or exposure to other
             investigational agent, device or procedure within 30 days

          6. Evidence of QTcF prolongation defined as &gt; 450 ms for males and &gt; 470 ms for females
             at screening

          7. Creatinine clearance (CrCl) &lt; 50 mL/min (Cockcroft-Gault formula) at screening

          8. Breast-feeding women

          9. History of meningococcal disease

         10. No vaccination against N. meningitidis types A, C, W, Y and B (administered as two
             separate vaccinations), Pneumococcal conjugate vaccine or Pneumococcal polysaccharide
             vaccine 23 (PCV13 or PPSV23, respectively) and Haemophilus influenzae Type B (Hib)
             vaccination within 2 years prior to Day 1 (Visit 2) dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Grossi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Apellis Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jane Anne Nohl Division of Hematology Keck-USC School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakes Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Lousiville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

